Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0PPRCD |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-mAb304 |
|||||
| Organization | EXELIXIS, INC. |
|||||
| Synonyms |
Anti-mAb304
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Varible Domain |
DTAVYYCTRGDRFAYWGOGTLVTVSS(SEOIDNO:9)
Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
PWTFGGGTKVEIK(SEOIDNO:8)
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
TW202444426A ADC-034 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
5.72 nM
|
Positive XXX expression (XXX+++/++) | ||
| Method Description |
The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
|
||||
| In Vitro Model | Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary | COV434-AMRH2 cells | CVCL_2010 | ||
TW202444426A ADC-033 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
37.17 nM
|
Positive XXX expression (XXX+++/++) | ||
| Method Description |
The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
|
||||
| In Vitro Model | Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary | COV434-AMRH2 cells | CVCL_2010 | ||
TW202444426A ADC-032 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
308.55 nM
|
Positive XXX expression (XXX+++/++) | ||
| Method Description |
The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
|
||||
| In Vitro Model | Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary | COV434-AMRH2 cells | CVCL_2010 | ||
TW202444426A ADC-031 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
881.76 nM
|
Positive XXX expression (XXX+++/++) | ||
| Method Description |
The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
|
||||
| In Vitro Model | Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary | COV434-AMRH2 cells | CVCL_2010 | ||